Non-inferiority testing for risk ratio, odds ratio and number needed to treat in three-arm trial

Three-arm non-inferiority (NI) trial including the experimental treatment, an active reference treatment, and a placebo where the outcome of interest is binary are considered. While the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness),...

Full description

Saved in:
Bibliographic Details
Published inComputational statistics & data analysis Vol. 132; pp. 70 - 83
Main Authors Chowdhury, Shrabanti, Tiwari, Ram C., Ghosh, Samiran
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.04.2019
Subjects
Online AccessGet full text
ISSN0167-9473
1872-7352
DOI10.1016/j.csda.2018.08.018

Cover

More Information
Summary:Three-arm non-inferiority (NI) trial including the experimental treatment, an active reference treatment, and a placebo where the outcome of interest is binary are considered. While the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness), however, recent FDA guideline suggested measures such as relative risk (RR), odds ratio (OR), number needed to treat (NNT) among others, on the basis of which NI can be claimed for binary outcome. Albeit, developing test based on these different functions of binary outcome are challenging. This is because the construction and interpretation of NI margin for such functions are non-trivial extensions of RD based approach. A Frequentist test based on traditional fraction margin approach for RR, OR and NNT are proposed first. Furthermore a conditional testing approach is developed by incorporating assay sensitivity (AS) condition directly into NI testing. A detailed discussion of sample size/power calculation are also put forward which could be readily used while designing such trials in practice. A clinical trial data is reanalyzed to demonstrate the presented approach.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-9473
1872-7352
DOI:10.1016/j.csda.2018.08.018